Why U.S. healthcare market entry is a compliance project
Foreign healthcare and health-technology companies are often attracted to the size and sophistication of the U.S. market. But the United States does not have a single healthcare regulator or a single compliance rulebook. Federal and state laws can overlap across reimbursement, fraud and abuse, privacy, professional licensing, marketing, device regulation, laboratory activity, corporate practice restrictions, and payer contracting.
A company can therefore have a commercially strong product and still fail because its revenue model, referral relationships, compensation arrangements, data flows, or contracting assumptions do not fit the U.S. regulatory environment. Market-entry planning should identify those risks before sales teams, investors, and distributors build a model around assumptions that later need to be unwound.
Start with the revenue model
The first question should be how the company expects to get paid. Direct consumer payment, employer contracts, commercial insurance, Medicare, Medicaid, provider partnerships, licensing fees, subscriptions, and technology-service arrangements create very different regulatory profiles. A business that touches federal healthcare program reimbursement may face fraud-and-abuse rules that do not apply in the same way to a pure consumer wellness product.
The company should map who bills, who receives money, who refers business, who controls clinical decisions, and whether compensation varies with patient volume or reimbursed services. Those facts often determine the compliance analysis more than the marketing description of the product.
Fraud-and-abuse laws and referral relationships
The federal Anti-Kickback Statute and related fraud-and-abuse rules can affect arrangements involving remuneration intended to generate or reward federal healthcare program business. The Stark Law can restrict certain physician self-referral arrangements. The False Claims Act can create exposure where false claims are knowingly submitted or caused to be submitted. State laws may be broader or apply even when federal program dollars are not involved.
Foreign companies should be particularly careful when adapting commercial practices that are common elsewhere, such as referral fees, percentage-based marketing compensation, free services, gifts to clinicians, distributor incentives, or joint ventures tied to patient volume. A model that is accepted in another jurisdiction may be problematic in the United States.
Compliance infrastructure matters early
HHS OIG’s General Compliance Program Guidance describes the traditional seven elements of a compliance program and emphasizes adaptation to organizational size and risk. A smaller entrant does not need the bureaucracy of a hospital system, but it should have clear responsibility, standards, training, reporting channels, auditing or monitoring, consistent discipline, and procedures for responding to identified problems.
This is particularly important for companies seeking U.S. investors, strategic partners, or healthcare customers. Sophisticated counterparties may evaluate whether the company has a credible compliance structure before entering a long-term relationship.
Healthcare technology and data issues
Digital-health and technology companies often assume that all health information is governed by HIPAA. The actual analysis is more specific. HIPAA applies to covered entities and business associates, while other federal and state privacy laws may govern consumer health information outside HIPAA. Companies should determine who collects data, for what purpose, under whose authority, where the data is stored, and whether the company is acting as a business associate or independent service provider.
Data architecture should be reviewed before implementation. Contract promises regarding privacy and security should match the technical system, and the company should know which incidents trigger notification or contractual duties.
Professional licensing and corporate-practice restrictions
Healthcare delivery is regulated heavily at the state level. Telemedicine, nursing, pharmacy, dentistry, laboratory services, behavioral health, and other clinical activities can require professional licensure in the patient’s state. Some states also restrict corporate ownership or control of professional practices.
A foreign company should not assume that forming a Delaware corporation allows it to employ clinicians or deliver services nationwide. The operating model should be reviewed state by state where necessary, especially when the company itself intends to provide or control clinical services.
Sales, marketing, and third parties
Healthcare businesses often rely on marketing companies, brokers, consultants, management organizations, and referral sources. Compensation models should be reviewed before contracts are signed. Percentage compensation, per-patient payments, lead-generation fees, and arrangements linked to reimbursed services can create significant risk depending on the facts.
Third-party diligence should also examine ownership, exclusions, past enforcement, professional discipline, sanctions, and the actual services being provided. A polished agreement does not cure a commercially improper relationship.
Preparing for U.S. diligence
Foreign companies raising capital or entering strategic transactions should expect U.S. investors and acquirers to examine compliance. They may ask for billing policies, coding audits, payer correspondence, physician contracts, marketing agreements, privacy incidents, government inquiries, licenses, exclusions screening, and compliance-program materials.
A pre-entry or pre-transaction compliance review can identify issues early enough to remediate them before they affect valuation or closing. This is often less disruptive than attempting to reconstruct compliance after a buyer or regulator identifies the problem.
A phased compliance roadmap for market entry
Foreign healthcare companies should sequence compliance work around the actual launch plan. Before entity formation or contracting, management should define the product or service, expected customers, payer mix, clinical role, data flows, marketing channels, and states of operation. Those facts determine which legal and regulatory workstreams are material. Attempting to solve every U.S. healthcare issue at once is inefficient; ignoring them until launch is riskier.
In the next phase, the company should align contracts and operations with the regulatory model. This may include provider agreements, business-associate terms, marketing arrangements, billing processes, professional-entity structures, state registrations, privacy notices, security responsibilities, and internal approval controls. The company should also identify which functions require U.S. counsel, coding or reimbursement specialists, privacy professionals, or other licensed advisers.
After launch, monitoring becomes important. Management should review complaints, billing denials, payer audits, referral arrangements, privacy incidents, marketing practices, licensing status, and changes in reimbursement. A company entering the United States should expect its compliance model to evolve as the business grows. Building review points into the operating plan is more effective than waiting for a regulator, payer, investor, or customer to identify a weakness.
How Axon Point Advisory Can Help
Axon Point Advisory assists companies, investors, boards, and professional advisers with cross-border risk assessments, factual investigations, counterparty and transaction due diligence, compliance-program design, remediation planning, and coordination of complex matters involving the United States, Armenia, and international markets. Where a matter requires legal advice, legal representation, or a formal legal opinion, that work should be handled under a separate engagement with appropriately licensed counsel.
Frequently Asked Questions
Does every health-tech company need HIPAA compliance?
Not necessarily. HIPAA status depends on the company’s role and relationships, although other privacy obligations may still apply.
Can a foreign company hire U.S. doctors directly?
It depends on state law, professional licensing, corporate-practice rules, and the operating model.
Are referral commissions always prohibited?
No, but healthcare compensation arrangements can be highly fact-specific and should be reviewed before implementation.
Should a startup build a full hospital-style compliance department?
Usually not. OIG guidance supports adapting the program to size and risk while maintaining core compliance functions.
Selected official sources
- HHS OIG General Compliance Program Guidance: Official source
- DOJ Corporate Compliance Materials: Official source
This article is provided for general informational and business-advisory purposes and does not constitute legal advice. Laws, regulations, sanctions, and enforcement policies change. Legal advice should be obtained from appropriately licensed counsel for a specific matter.